To further understand the cellular consequence of MYD88L265P in combination with TNFAIP3 loss in human models of WM and DLBCL, we used TALENs genome editing technology to genetically modify the WM cell line MWCL and the ABC-DLBCL cell line HBL-1, both of which harbor a MYD88L265P mutation, but have a wild type TNFAIP3. To introduce a TNFAIP3 loss in those cell lines, we designed a unique pair of TALENs to target exon 5 of the TNFAIP3 gene to induce a double strand break resulting in a base pair deletions in exon 5 (Fig. 1d). The gene discussed is TNFAIP3; the disease is diffuse large B-cell lymphoma.